In this paper we present a software whiteboard for multimedia conferences. The whiteboard is specialised to load and share high-resolution colour images while using colour management functions to ...provide an accurate colour representation. The whiteboard is used in the telemedicine project INTER-FACE, which builds a virtual environment for tele-consultations between specialists in pre-operative treatment and the planning of the cranio-maxillofacial surgery for patients with facial abnormalities.
A concept for an electronic magazine von Berg, Alexander; Pralle, Helmut
Computer networks (1999),
11/1999, Letnik:
31, Številka:
21
Journal Article, Conference Proceeding
Recenzirano
This paper describes the concept for an electronic magazine (EZine) based on the World Wide Web. The project aims at creating an electronic magazine as the online version of an already existing ...printed scientific magazine, which will primarily supply the content. The articles in this EZine contain various types of media, including text, images, audio, video and 3D objects. A keyword search as well as subscription is supported. Articles can be accessed by the readers via collections or via search mechanisms. The paper gives an overview of the general design of the EZine and focuses on some key aspects of the concept.
The current document summarizes the experiences obtained during the maintenance and operations of the cache hierarchy within the German broadband research network. Installed at central nodes, the ...cache service is an integral part of the backbone infrastructure. Ten distributed cache servers are the building blocks of a large scale top-level cache hierarchy. Since the beginning in January 1997, the DFN cache service was subjected to different mesh designs and conceptions. Various approaches were aimed at improvements in the load and traffic balance among the caches. At the same time, the benefit of the mesh as whole was to be increased, as well. Due to the fact that the caches are used in a production-like environment, few of the variations thought of manifested themselves in practical configurations. Maintainers of similar cache meshes may benefit from our ideas and experiences related in this document for their own conceptual design, configuration, and hardware selection. The reader might want to investigate further publications describing the design of single web caching systems
1–4.
This paper presents the functionality and architecture of a new conference-control management system called Confman 2.0. It enables the user to initiate and participate in online conferences based on ...current Internet standards. Supported system platforms include Unix workstations and Microsoft operating systems as well. Starting with a short description of current Internet conferencing technology the paper describes Confman's conference-control functionality and gives a brief overview of Confman's distributed software architecture.
In this paper we describe a distributed system approach for three-dimensional exploration in the context of high-performance computing, which supports postprocessing, online-visualization and ...interactive steering scenarios. Our processing chain consists of three instances (data source, streaming server, viewer), which can be distributed in high-performance networks and operated either in a full pipeline (on-the-fly 3D visualization, computational steering) or in asynchronously running pairs (visualization of prepared 3D scenes). It takes advantage of parallel data extraction, efficient 3D representation, and streaming protocols over TCP/IP.
Early allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed as primary treatment modality for patients with chronic myeloid leukemia (CML). This concept has been challenged by ...transplantation mortality and improved drug therapy. In a randomized study, primary HSCT and best available drug treatment (IFN based) were compared in newly diagnosed chronic phase CML patients. Assignment to treatment strategy was by genetic randomization according to availability of a matched related donor. Evaluation followed the intention-to-treat principle. Six hundred and twenty one patients with chronic phase CML were stratified for eligibility for HSCT. Three hundred and fifty four patients (62% male; median age, 40 years; range, 11-59 years) were eligible and randomized. One hundred and thirty five patients (38%) had a matched related donor, of whom 123 (91%) received a transplant within a median of 10 months (range, 2-106 months) from diagnosis. Two hundred and nineteen patients (62%) had no related donor and received best available drug treatment. With an observation time up to 11.2 years (median, 8.9 years), survival was superior for patients with drug treatment (P = .049), superiority being most pronounced in low-risk patients (P = .032). The general recommendation of HSCT as first-line treatment option in chronic phase CML can no longer be maintained. It should be replaced by a trial with modern drug treatment first.
The influence of interferon-α (IFN) pretreatment on the outcome after allogeneic bone marrow transplantation (BMT) in chronic myelogenous leukemia (CML) is controversial. One goal of the German ...randomized CML Studies I and II, which compare IFN ± chemotherapy versus chemotherapy alone, was the analysis of whether treatment with IFN as compared to chemotherapy had an influence on the outcome after BMT. One hundred ninety-seven (23%) of 856 Ph/bcr-abl–positive CML patients were transplanted. One hundred fifty-two patients transplanted in first chronic phase were analyzed: 86 had received IFN, 46 hydroxyurea, and 20 busulfan. Forty-eight patients (32%) had received transplants from unrelated donors. Median observation time after BMT was 4.7 (0.7 to 13.5) years. IFN and chemotherapy cohorts were compared with regard to transplantation risks, duration of treatments, interval from discontinuation of pretransplant treatment to BMT, conditioning therapy, graft-versus-host disease prophylaxis and risk profiles at diagnosis and transplantation, and IFN cohorts also with regard to performance and resistance to IFN. Outcome of patients receiving related or unrelated transplants pretreated with IFN, hydroxyurea, or busulfan was not significantly different. Five-year survival after transplantation was 58% for all patients (57% for IFN, 60% for hydroxyurea and busulfan patients). The outcome within the IFN group was not different by duration of prior IFN therapy more or less than 5 months, 1 year, or 2 years. In contrast, a different impact was observed in IFN-pretreated patients depending on the time of discontinuation of IFN before transplantation. Five-year survival was 46% for the 50 patients who received IFN within the last 90 days before BMT and 71% for the 36 patients who did not (P = .0057). Total IFN dosage had no impact on survival after BMT. We conclude that outcome after BMT is not compromised by pretreatment with IFN if it is discontinued at least 3 months before transplantation. Clear candidates for early transplantation should not be pretreated with IFN.
Abstract
The influence of interferon- (IFN) pretreatment on the outcome after allogeneic bone marrow transplantation (BMT) in chronic myelogenous leukemia (CML) is controversial. One goal of the ...German randomized CML Studies I and II, which compare IFN ± chemotherapy versus chemotherapy alone, was the analysis of whether treatment with IFN as compared to chemotherapy had an influence on the outcome after BMT. One hundred ninety-seven (23%) of 856 Ph/bcr-abl–positive CML patients were transplanted. One hundred fifty-two patients transplanted in first chronic phase were analyzed: 86 had received IFN, 46 hydroxyurea, and 20 busulfan. Forty-eight patients (32%) had received transplants from unrelated donors. Median observation time after BMT was 4.7 (0.7 to 13.5) years. IFN and chemotherapy cohorts were compared with regard to transplantation risks, duration of treatments, interval from discontinuation of pretransplant treatment to BMT, conditioning therapy, graft-versus-host disease prophylaxis and risk profiles at diagnosis and transplantation, and IFN cohorts also with regard to performance and resistance to IFN. Outcome of patients receiving related or unrelated transplants pretreated with IFN, hydroxyurea, or busulfan was not significantly different. Five-year survival after transplantation was 58% for all patients (57% for IFN, 60% for hydroxyurea and busulfan patients). The outcome within the IFN group was not different by duration of prior IFN therapy more or less than 5 months, 1 year, or 2 years. In contrast, a different impact was observed in IFN-pretreated patients depending on the time of discontinuation of IFN before transplantation. Five-year survival was 46% for the 50 patients who received IFN within the last 90 days before BMT and 71% for the 36 patients who did not (P = .0057). Total IFN dosage had no impact on survival after BMT. We conclude that outcome after BMT is not compromised by pretreatment with IFN if it is discontinued at least 3 months before transplantation. Clear candidates for early transplantation should not be pretreated with IFN.
